GSK Wins Early FDA Nod for Nelkarmi

GSK (LON: GSK) received accelerated FDA approval for its lung cancer drug Nelkarmi (neladalkib) for ALK-positive non-small cell lung cancer. The approval, based on early trial data, came before the November 27 target date. GSK shares were down 0.16% at 1866p. The drug showed a 49% response rate in patients previously treated with alectinib. GSK also plans to acquire Nuvalent for $10.6bn.

Original reporting
Published Nov 18, 2026, 9:56 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 10:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
GSK Wins Early FDA Nod for Nelkarmi — source image
Decision brief

The 30-second read

$GSKBullishHigh
01

Why it matters

The approval advances GSK’s lung cancer franchise timeline and provides a near-term commercialization catalyst, but the conditional nature and liver-toxicity signal keep fundamental upside dependent on confirmatory evidence.

02

Market read

Traders can reassess GSK’s oncology launch optionality immediately, while also re-evaluating the probability-weighted path to confirmatory trial success given the safety profile.

03

What to watch

Hepatotoxicity is the main safety signal with 5% permanent discontinuations, which could constrain uptake and increase post-launch monitoring or label refinement risk.

Relevance 7/10Novelty 9/10Timing: pre-market today, with FDA accelerated approval reported at 7am

Background

Nelkarmi (neladalkib) received accelerated US approval for previously treated ALK-positive non-small cell lung cancer, based on ALKOVE-1 phase I/II data.

Company-level read

Ticker impact

$GSKBullishHigh confidence
Context

GSK says the FDA granted accelerated US approval for its lung cancer drug Nelkarmi (neladalkib) for previously treated ALK-positive NSCLC.

Expected impact

Likely upward bias as traders price in earlier commercialization optionality, while investors may discount some upside due to conditional approval and safety discontinuation risk.

Evidence & confidence

The article is a first-report style regulatory approval with specific label, trial basis, response rates, and a stated safety signal, which directly affects GSK’s near-term risk-reward for Nelkarmi.

Market effects

Reinforces investor appetite for ALK-targeted lung cancer assets and highlights the market’s focus on accelerated-approval durability and safety management.

Supports UK pharma sentiment via a US regulatory win, potentially improving cross-Atlantic biotech risk appetite.

US FDA oncology approvals can shift global expectations for ALK franchise competitiveness and trial read-throughs.

Counterpoint

Because the approval is accelerated and conditional on confirmatory trials, the market may treat it as incremental until ALKAZAR (phase III) validates benefit and tolerability.

Key entities

  • GSK

    London-listed drugmaker receiving accelerated FDA approval for Nelkarmi.

  • FDA

    US drug regulator granting accelerated approval ahead of the target date.

  • Nelkarmi (neladalkib)

    GSK lung cancer drug cleared for previously treated ALK-positive NSCLC under accelerated approval.

  • ALKOVE-1

    Phase I/II trial supporting the accelerated approval, with response rates reported by prior treatment group.

  • ALKAZAR

    Phase III trial in patients who have not had a TKI before, cited as part of the commercial case.

Related articles

$GSKMedAI 8/10

GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval

GSK's Nelkarmi (neladalkib) received FDA approval for treating ALK-positive non-small cell lung cancer, the second drug from its $10.6bn Nuvalent acquisition. The approval was based on trial results showing a 49% response rate. GSK expects significant sales, with forecasts predicting $1.2bn by 2032. Roche's Alecensa is a key competitor. Approval hinges on ongoing Phase III trial results.

$GSKMed

GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance

GSK (GSK) received FDA approval for Nelkarmi, a lung cancer drug, based on Phase 1/2 trial data. The drug targets ALK gene mutations and showed activity against brain metastases. GSK acquired Nelkarmi through its $10.6B Nuvalent deal. Analysts project $1B in 2032 sales, with peak sales estimates of $5B-$7B for GSK's lead Nuvalent drugs. The approval is seen as a validation of GSK's oncology portfolio strategy.

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$GSKMed

GSK gets second cancer drug approval from Nuvalent buy

GSK's Nelkarmi (neladalkib) received FDA approval for ALK-positive NSCLC after prior ALK inhibitor treatments. The approval follows GSK's $10.6B acquisition of Nuvalent. Analysts project Nelkarmi, Jideytro, and NVL-330 could generate $5B-$7B in annual sales. Nelkarmi showed a 49% objective response rate in trials. GSK aims to boost revenues to £40B by 2031.

$GSKMed

GSK wins early FDA approval for lung cancer drug Nelkarmi

GSK received early FDA approval for its lung cancer drug Nelkarmi, based on trial data showing meaningful responses in patients with prior ALK inhibitor therapies. The drug demonstrated a 49% response rate in patients with one prior treatment and 32% in those with multiple treatments. GSK noted the approval strengthens its oncology portfolio and addresses unmet needs in ALK-positive lung cancer. As of 1010 GMT, GSK shares were down 0.08% at 1,867.50p.

$GSKMed

FDA Grants Accelerated Approval to Neladalkib for ALK Positive Lung Cancer

The FDA granted accelerated approval to GSK’s neladalkib (Nelkarmi) for adults with previously treated ALK-positive metastatic or locally advanced NSCLC. Based on the Phase I/II ALKOVE-1 trial, confirmed ORR was 49% (after alectinib) and 32% (after multiple ALK TKIs plus platinum), with intracranial ORR 55% and 26%. Key safety issues included hepatotoxicity (56%).